[1] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1): 11-20.
[2] Pennisi G, Enea M, Falco V, et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes[J]. Hepatology,2023,78(1): 195-211.
[3] Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts[J]. BMC Med,2019,17(1): 95.
[4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol,2021,75(3): 659-689.
[5] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology,2023,77(5): 1797-1835.
[6] Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH[J]. Gastroenterology,2015,149(2): 278-281.
[7] Ekstedt M, Hagstr?m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology,2015,61(5): 1547-1554.
[8] Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C[J]. Hepatology, 2003,38(6): 1449-1457.
[9] Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD[J]. Nat Rev Endocrinol,2022,18(1): 55-66.
[10] Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol,2019,7(4): 313-324.
[11] Xia T, Du M, Li H, et al. Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk[J]. Radiology,2023,309(1): e231007.
[12] Micek M, Aebisher D, Surówka J, et al. Applications of T(1) and T(2) relaxation time calculation in tissue differentiation and cancer diagnostics-a systematic literature review[J]. Front Oncol,2022,12: 1010643.
[13] Terzi F, Camargo GC, Parente DB, et al. How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease[J]. J Clin Med,2023,12(23): 7381.
[14] Hoffman DH, Ayoola A, Nickel D, et al. T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis[J]. Abdom Radiol (NY),2020,45(3): 692-700.
[15] Duan T, Jiang H, Xia C, et al. Assessing Liver Function in Liver Tumors Patients: ,The Performance of T1 Mapping and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI[J]. Front Med (Lausanne),2020,7: 215.
[16] Li J, Gao X, Dominik Nickel M, et al. Native T1 mapping for differentiating the histopathologic type, grade, and stage of rectal adenocarcinoma: a pilot study[J]. Cancer Imaging,2022,22(1): 30.
[17] Muthupillai R, Lomas DJ, Rossman PJ, et al. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves[J]. Science,1995,269(5232): 1854-1857.
[18] Kennedy P, Wagner M, Castéra L, et al. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions[J]. Radiology,2018,286(3): 738-763.
[19] Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut,2020,69(7): 1343-1352.
[20] Yoneda M, Nakajima A. The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities[J]. Hepatology,2023,78(4): 1020-1022.
[21] Li J, Lu X, Zhu Z, et al. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH[J]. Hepatology,2023,78(4): 1200-1208.
[22] Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis[J]. Gut,2021,70(10): 1946-1953.
[23] Lee JS, Lee HW, Kim BK, et al. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria[J]. Front Med (Lausanne),2022,9: 869190.
[24] Cardoso AC, Tovo CV, Leite NC, et al. Validation and Performance of FibroScan○R-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease[J]. Dig Dis Sci,2022,67(11): 5272-5279. |
